PLC9 Antibody
Description
L9 Antibody in Malaria Research
The L9 antibody is a potent human monoclonal antibody (mAb) targeting the Plasmodium falciparum circumsporozoite protein (PfCSP), a critical antigen in malaria vaccine development. Key findings include:
-
Structure and Mechanism:
-
L9 binds preferentially to NVDP minor repeats and cross-reacts with NANP major repeats on PfCSP .
-
Its light chain (L9κ) is critical for cross-linking adjacent NVDP repeats, enabling high-affinity binding and potent sporozoite neutralization .
-
Cryo-EM studies reveal homotypic interactions between L9 Fabs, stabilizing multivalent binding to PfCSP minor repeats .
-
-
Functional Insights:
| Property | L9 Antibody | Related Antibodies |
|---|---|---|
| Target | NVDP and NANP repeats of PfCSP | NPNA-specific anti-PfCSP mAbs |
| Binding Mechanism | Cross-links two NVDP repeats via homotypic Fab interactions | Homotypic interfaces for NPNA repeats |
| Light Chain Role | L9κ essential for NVDP selectivity and neutralization | Heavy-chain-dominant binding in NPNA mAbs |
PLCG2 Antibodies
While not directly related to "PLC9," antibodies targeting phospholipase C-gamma-2 (PLCG2) are discussed in the context of immune regulation and disease:
-
Function: PLCG2 regulates immune cell activation via diacylglycerol (DAG) and inositol trisphosphate (IP3) signaling .
-
Antibody Validation:
Antibody Therapeutics and Engineering
The search results include data on engineered antibodies with clinical applications, though none align with "PLC9":
-
Examples:
Antibody Validation and Reproducibility
Standardized protocols for antibody validation highlight challenges in reliability:
Product Specs
Components: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Phosphatidylinositol-specific phospholipase C (PLC) enzymes mediate the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).
- Studies suggest that Arabidopsis thaliana PLC3 (AtPLC3) and AtPLC9 may share mechanisms in regulating thermotolerance, indicated by similar expression patterns and resulting phenotypes. PMID: 27070271
- At4g38530 and AtPLC9 demonstrate an additive effect on thermotolerance in Arabidopsis thaliana. PMID: 25149227
- AtPLC9 plays a critical role in conferring thermotolerance in Arabidopsis thaliana. PMID: 22007900
Q&A
FAQ Collection for PLC9 Antibody Research
This collection addresses scientific inquiries related to PLC9 antibody applications in malaria research, emphasizing experimental design, data validation, and advanced methodological strategies. Questions are categorized into basic and advanced tiers, with evidence-based answers drawn from peer-reviewed studies and technical guidelines.
Advanced Research Questions
How to resolve contradictions in PLC9 antibody reactivity across assays?
Discrepancies between ELISA, Western blot, and IF often arise from:
-
Epitope accessibility: Linear epitopes (e.g., peptide 4) dominate ELISA responses, while conformational epitopes may govern IF signals .
-
Post-translational modifications: CLAG9 undergoes phosphorylation in erythrocytes, altering antibody binding in native vs. denatured states .
Methodological recommendations:
-
Perform antigen retrieval under non-reducing conditions for IF.
-
Validate findings using independent antibodies targeting distinct CLAG9 domains .
What strategies improve PLC9 antibody manufacturability for therapeutic use?
-
Humanization: Graft PLC9-specific CDRs onto human frameworks (e.g., VH3-23/VK1-39) to reduce immunogenicity while retaining affinity .
-
Expression optimization: Use CHO cells for higher yields (≥2 g/L) compared to HEK293 (≤0.5 g/L) .
| Parameter | Chimeric Antibody | Humanized Antibody |
|---|---|---|
| Aggregation (%) | 15% | 3% |
| Expression (g/L) | 0.8 | 2.1 |
| Immunogenicity Risk | High | Moderate |
Data from antibody engineering case studies
How to design longitudinal studies assessing PLC9 antibody durability?
-
Sampling frequency: Collect sera every 3–6 months to capture antibody decay kinetics .
-
Endpoints: Measure both IgG titers (ELISA) and functional inhibition of cytoadherence (flow cytometry) .
-
Confounding factors: Adjust for malaria incidence rates and antimalarial drug use in statistical models .
